Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Roche has bought exclusive rights to codevelop and cocommercialize Actelion's orally active, selective S1P1 receptor agonist for the treatment of multiple autoimmune disorders. Actelion will receive a $75 million up-front payment from Roche and stands to reap another $555 million in milestones if the drug reaches the market in the targeted indications. As part of the deal, Roche also gains access to other selective S1P1 receptor agonists that come out of Actelion's labs.
This article has been sent to the following recipient: